Figure 2.
IL-2/IL-2Ab treatment has little influence on non-Treg populations. A, Gating strategy for CD3−B220+ B cells, CD3+CD4+ T cells, CD3+CD8+ T cells, NK1.1+ NK cells, Gr1+ neutrophils, and CD115+ monocytes. B–E, Percentages of peripheral B cells, CD4+ T cells, CD8+ T cells, NK cells, neutrophils, and monocytes in blood (B, C) and spleen (D, E) showed no change after IL-2/IL-2Ab treatment. n = 5–9/group.